Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab Plus R-CHOP in Untreated Mantle Cell Lymphoma
NCT00401817Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Nov 2007
- Primary completion
- Jul 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in mantle cell lymphoma (MCL), sponsored by Weill Cornell Medicine. Started Nov 2007; status: completed.
02
Drugs
bevacizumab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00401817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00401817.